Clinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones

[EN] BACKGROUND: Quinolones are the second most frequent cause of hypersensitivity reactions (HSRs) to antibiotics. A marked increase in the number of patients with HSRs to quinolones has been detected. OBJECTIVE: To describe the clinical characteristics of patients with HSRs to quinolones and present methods for their diagnosis. METHODS: Patients attending the allergy unit due to reactions suggestive of HSRs to quinolones were prospectively evaluated between 2005 and 2018. Diagnosis was achieved using clinical history, skin tests (STs), basophil activation tests (BATs), and drug provocation tests (DPTs) if ST and BAT results were negative. RESULTS: We included 128 subjects confirmed as having HSRs to quinolones and 42 found to be tolerant. Anaphylaxis was the most frequent entity in immediate HSRs and was most commonly induced by moxifloxacin. Patients were evaluated a median of 150 days (interquartile range, 60-365 days) after the reaction. Of patients who underwent ST and BAT, 40.7% and 70%, respectively, were positive. DPT with a quinolone was performed in 48 cases, giving results depending on the culprit drug: when moxifloxacin was involved, 62.5% of patients gave a positive DPT result to ciprofloxacin, whereas none reacted to levofloxacin. The risk of HSR was 96 times higher in subjects who reported moxifloxacin-induced anaphylaxis and 18 times higher in those reporting immediate reactions compared with clinical entities induced by quinolones other than moxi-floxacin and nonimmediate reactions. CONCLUSIONS: The diagnosis of HSR to quinolones is complex. The use of clinical history is essential as a first step. BAT shows higher sensitivity than STs. DPTs can be useful for finding safe alternative quinolones.The present study has been supported by the Institute of Health "Carlos III" of the Ministry of Economy and Competitiveness (grants cofounded by European Regional Development Fund: RETIC ARADYALRD16/0006/0001, RD16/0006/0010, RD16/0006/0019, and RD16/0006/0030). I.D. is a clinical investigator (B0001-2017) from Consejeria de Salud of the Andalusian government, Junta de Andalucia. N.P.-S. holds a Rio Hortega research contract (CM17/0014), and E.B. a Juan Rodes research contract (JR18/00049), both from the Institute of Health "Carlos III," Spanish Ministry of Economy and Competitiveness (grants cofounded by the European Social Fund).Doña, I.; Pérez-Sánchez, N.; Salas, M.; Barrionuevo, E.; Ruiz-San Francisco, A.; Hernández Fernández De Rojas, D.; Martí-Garrido, J.... (2020). Clinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones. Journal of Allergy and Clinical Immunology: In Practice. 8(8):2707-2714. https://doi.org/10.1016/j.jaip.2020.04.051S2707271488Campi, P., & Pichler, W. J. (2003). Quinolone hypersensitivity. Current Opinion in Allergy and Clinical Immunology, 3(4), 275-281. doi:10.1097/00130832-200308000-00007Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., … Hoban, D. J. (2002). A Critical Review of the Fluoroquinolones. Drugs, 62(1), 13-59. doi:10.2165/00003495-200262010-00002Bertino, J., & Fish, D. (2000). The safety profile of the fluoroquinolones. Clinical Therapeutics, 22(7), 798-817. doi:10.1016/s0149-2918(00)80053-3Ho, D. Y., Song, J. C., & Wang, C. C. (2003). Anaphylactoid Reaction to Ciprofloxacin. Annals of Pharmacotherapy, 37(7-8), 1018-1023. doi:10.1345/aph.1c498Demoly, P., Adkinson, N. F., Brockow, K., Castells, M., Chiriac, A. M., Greenberger, P. A., … Thong, B. Y.-H. (2014). International Consensus on drug allergy. Allergy, 69(4), 420-437. doi:10.1111/all.12350Schmid, D. A., Depta, J. P. H., & Pichler, W. J. (2006). T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clinical Experimental Allergy, 36(1), 59-69. doi:10.1111/j.1365-2222.2006.02402.xJones, S. C., Budnitz, D. S., Sorbello, A., & Mehta, H. (2013). US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions. Pharmacoepidemiology and Drug Safety, 22(10), 1099-1106. doi:10.1002/pds.3499Sachs, B., Fischer-Barth, W., & Merk, H. F. (2015). Reporting rates for severe hypersensitivity reactions associated with prescription-only drugs in outpatient treatment in Germany. Pharmacoepidemiology and Drug Safety, 24(10), 1076-1084. doi:10.1002/pds.3857McNeil, B. D., Pundir, P., Meeker, S., Han, L., Undem, B. J., Kulka, M., & Dong, X. (2014). Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature, 519(7542), 237-241. doi:10.1038/nature14022Van Gasse, A. L., Sabato, V., Uyttebroek, A. P., Elst, J., Faber, M. A., Hagendorens, M. M., … Ebo, D. G. (2017). Immediate moxifloxacin hypersensitivity: Is there more than currently meets the eye? Allergy, 72(12), 2039-2043. doi:10.1111/all.13236Porebski, G., Kwiecien, K., Pawica, M., & Kwitniewski, M. (2018). Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions. Frontiers in Immunology, 9. doi:10.3389/fimmu.2018.03027González-Gregori, R., Dolores Hernández Fernandez De Rojas, M., López-Salgueiro, R., Díaz-Palacios, M., & García, A. N. (2012). Allergy alerts in electronic health records for hospitalized patients. Annals of Allergy, Asthma & Immunology, 109(2), 137-140. doi:10.1016/j.anai.2012.06.006Renaudin, J.-M., Beaudouin, E., Ponvert, C., Demoly, P., & Moneret-Vautrin, D.-A. (2013). Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. Allergy, 68(7), 929-937. doi:10.1111/all.12168Blanca-López, N., Ariza, A., Doña, I., Mayorga, C., Montañez, M. I., Garcia-Campos, J., … Torres, M. J. (2013). Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clinical & Experimental Allergy, 43(5), 560-567. doi:10.1111/cea.12099Johannes, C. B., Ziyadeh, N., Seeger, J. D., Tucker, E., Reiter, C., & Faich, G. (2007). Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation. Drug Safety, 30(8), 705-713. doi:10.2165/00002018-200730080-00007Kulthanan, K., Chularojanamontri, L., Manapajon, A., Dhana, N., & Jongjarearnprasert, K. (2011). Cutaneous Adverse Reactions to Fluoroquinolones. Dermatitis, 22(3), 155-160. doi:10.2310/6620.2011.10115Neuman, M. G., Cohen, L. B., & Nanau, R. M. (2015). Quinolones-induced hypersensitivity reactions. Clinical Biochemistry, 48(10-11), 716-739. doi:10.1016/j.clinbiochem.2015.04.006Phillips, C. J., Gilchrist, M., Cooke, F. J., Franklin, B. D., Enoch, D. A., Murphy, M. E., … Holmes, A. H. (2019). Adherence to antibiotic guidelines and reported penicillin allergy: pooled cohort data on prescribing and allergy documentation from two English National Health Service (NHS) trusts. BMJ Open, 9(2), e026624. doi:10.1136/bmjopen-2018-026624Dávila, I., Diez, M. L., Quirce, S., Fraj, J., Hoz, B., & Lazaro, M. (1993). Cross-reactivity between quinolones. Allergy, 48(5), 388-390. doi:10.1111/j.1398-9995.1993.tb02413.xScherer, K., & Bircher, A. J. (2005). Hypersensitivity reactions to fluoroquinolones. Current Allergy and Asthma Reports, 5(1), 15-21. doi:10.1007/s11882-005-0049-1Brockow, K., Garvey, L. H., Aberer, W., Atanaskovic-Markovic, M., Barbaud, A., … Bilo, M. B. (2013). Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy, 68(6), 702-712. doi:10.1111/all.12142Manfredi, M., Severino, M., Testi, S., Macchia, D., Ermini, G., Pichler, W. J., & Campi, P. (2004). Detection of specific IgE to quinolones. Journal of Allergy and Clinical Immunology, 113(1), 155-160. doi:10.1016/j.jaci.2003.09.035Aranda, A., Mayorga, C., Ariza, A., Doña, I., Rosado, A., Blanca-Lopez, N., … Torres, M. J. (2010). In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy, 66(2), 247-254. doi:10.1111/j.1398-9995.2010.02460.xBen Said, B., Berard, F., Bienvenu, J., Nicolas, J.-F., & Rozieres, A. (2010). Usefulness of basophil activation tests for the diagnosis of IgE-mediated allergy to quinolones. Allergy, 65(4), 535-536. doi:10.1111/j.1398-9995.2009.02213.xMayorga, C., Celik, G., Rouzaire, P., Whitaker, P., Bonadonna, P., … Rodrigues-Cernadas, J. (2016). In vitrotests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy, 71(8), 1103-1134. doi:10.1111/all.12886Seitz, C. S., Bröcker, E. B., & Trautmann, A. (2009). Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clinical & Experimental Allergy, 39(11), 1738-1745. doi:10.1111/j.1365-2222.2009.03338.xBrockow, K., Ardern‐Jones, M. R., Mockenhaupt, M., Aberer, W., Barbaud, A., Caubet, J., … Mortz, C. G. (2018). EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy, 74(1), 14-27. doi:10.1111/all.13562Valdivieso, R., Pola, J., Losada, E., Subiza, J., Armentia, A., & Zapata, C. (1988). Severe anaphylactoid reaction to nalidixic acid. Allergy, 43(1), 71-73. doi:10.1111/j.1398-9995.1988.tb02046.xAberer, W., Bircher, A., Romano, A., Blanca, M., Campi, P., … Fernandez, J. (2003). Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy, 58(9), 854-863. doi:10.1034/j.1398-9995.2003.00279.xSALVO, F., POLIMENI, G., CUTRONEO, P., LEONE, R., CONFORTIC, A., MORETTI, U., … CAPUTI, A. (2008). Allergic reactions to oral drugs: A case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacological Research, 58(3-4), 202-207. doi:10.1016/j.phrs.2008.07.003Blanca, M., Romano, A., Torres, M. J., Férnandez, J., Mayorga, C., Rodriguez, J., … Atanasković-Marković, M. (2009). Update on the evaluation of hypersensitivity reactions to betalactams. Allergy, 64(2), 183-193. doi:10.1111/j.1398-9995.2008.01924.xBircher, A. J., & Scherer Hofmeier, K. (2012). Drug hypersensitivity reactions: Inconsistency in the use of the classification of immediate and nonimmediate reactions. Journal of Allergy and Clinical Immunology, 129(1), 263-264. doi:10.1016/j.jaci.2011.08.042Terrados, S., Blanca, M., Garcia, J., Vega, J., Torres, M. J., Carmona, M. J., … Fernandez, J. (1995). Nonimmediate reactions to betalactams: prevalence and role of the different penicillins. Allergy, 50(7), 563-567. doi:10.1111/j.1398-9995.1995.tb01200.xGómez, E., Blanca-Lopez, N., Salas, M., Canto, G., Campo, P., Torres, M. J., … Blanca, M. (2013). Induction of accelerated reactions to amoxicillin by T-cell effector mechanisms. Annals of Allergy, Asthma & Immunology, 110(4), 267-273. doi:10.1016/j.anai.2013.01.003Blanca-López, N., Pérez-Sánchez, N., Agúndez, J. A., García-Martin, E., Torres, M. J., Cornejo-García, J. A., … Doña, I. (2016). Allergic Reactions to Metamizole: Immediate and Delayed Responses. International Archives of Allergy and Immunology, 169(4), 223-230. doi:10.1159/000444798Alonso, M. D., Martín, J. A., Quirce, S., Dávila, I., Lezaun, A., & Cano, M. S. (1993). Fixed eruption caused by ciprofloxacin with cross-sensitivity to norfloxacin. Allergy, 48(4), 296-297. doi:10.1111/j.1398-9995.1993.tb00733.xDavila, G., Ruiz-Hornillos, J., Rojas, P., De Castro, F., & Zubeldia, J. M. (2009). TOXIC EPIDERMAL NECROLYSIS INDUCED BY LEVOFLOXACIN. Annals of Allergy, Asthma & Immunology, 102(5), 441-442. doi:10.1016/s1081-1206(10)60521-2Ayllón, M. L., Martinez, M. G., Mosquera, M. R., Laguna Martinez, J. J., Martiartu, M. O., & Fernández de Miguel, C. (1995). Fixed eruption caused by ciprofloxacin without cross-sensitivity to norfloxacin. Allergy, 50(7), 598-599. doi:10.1111/j.1398-9995.1995.tb01206.xEmpedrad, R. (2003). Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. Journal of Allergy and Clinical Immunology, 112(3), 629-630. doi:10.1016/s0091-6749(03)01783-4Brož, P., Harr, T., Hecking, C., Grize, L., Scherer, K., Jaeger, K. A., & Bircher, A. J. (2012). Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy, 67(5), 647-652. doi:10.1111/j.1398-9995.2012.02807.xUyttebroek, A. P., Sabato, V., Bridts, C. H., De Clerck, L. S., & Ebo, D. G. (2015). Moxifloxacin hypersensitivity: Uselessness of skin testing. The Journal of Allergy and Clinical Immunology: In Practice, 3(3), 443-445. doi:10.1016/j.jaip.2014.12.012Fernandez-Rivas, M. (1997). Fixed drug eruption (FDE) caused by norfloxacin. Allergy, 52(4), 477-478. doi:10.1111/j.1398-9995.1997.tb01035.xChang, B., Knowles, S. R., & Weber, E. (2010). Immediate Hypersensitivity to Moxifloxacin with Tolerance to Ciprofloxacin: Report of Three Cases and Review of the Literature. Annals of Pharmacotherapy, 44(4), 740-745. doi:10.1345/aph.1m579Sánchez-Morillas, L., Rojas Pérez-Ezquerra, P., Reaño-Martos, M., Laguna-Martínez, J. J., & Gómez-Tembleque, P. (2010). Systemic anaphylaxis caused by moxifloxacin. Allergologia et Immunopathologia, 38(4), 226-227. doi:10.1016/j.aller.2009.09.00

Genomic investigations of unexplained acute hepatitis in children

Since its first identification in Scotland, over 1000 cases of unexplained pediatric hepatitis in children have been reported worldwide, including 278 cases in the UK. Here we report investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator subjects, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in liver, blood, plasma or stool from 27/28 cases. We found low levels of Adenovirus (HAdV) and Human Herpesvirus 6B (HHV-6B), in 23/31 and 16/23 respectively of the cases tested. In contrast, AAV2 was infrequently detected at low titre in blood or liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T-cells and B-lineage cells. Proteomic comparison of liver tissue from cases and healthy controls, identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and in severe cases HHV-6B, may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children

Measurement of χ c1 and χ c2 production with s√ = 7 TeV pp collisions at ATLAS

The prompt and non-prompt production cross-sections for the χ c1 and χ c2 charmonium states are measured in pp collisions at s√ = 7 TeV with the ATLAS detector at the LHC using 4.5 fb−1 of integrated luminosity. The χ c states are reconstructed through the radiative decay χ c → J/ψγ (with J/ψ → μ + μ −) where photons are reconstructed from γ → e + e − conversions. The production rate of the χ c2 state relative to the χ c1 state is measured for prompt and non-prompt χ c as a function of J/ψ transverse momentum. The prompt χ c cross-sections are combined with existing measurements of prompt J/ψ production to derive the fraction of prompt J/ψ produced in feed-down from χ c decays. The fractions of χ c1 and χ c2 produced in b-hadron decays are also measured

Measurements of fiducial and differential cross sections for Higgs boson production in the diphoton decay channel at s√=8 TeV with ATLAS

Measurements of fiducial and differential cross sections are presented for Higgs boson production in proton-proton collisions at a centre-of-mass energy of s√=8 TeV. The analysis is performed in the H → γγ decay channel using 20.3 fb−1 of data recorded by the ATLAS experiment at the CERN Large Hadron Collider. The signal is extracted using a fit to the diphoton invariant mass spectrum assuming that the width of the resonance is much smaller than the experimental resolution. The signal yields are corrected for the effects of detector inefficiency and resolution. The pp → H → γγ fiducial cross section is measured to be 43.2 ±9.4(stat.) − 2.9 + 3.2 (syst.) ±1.2(lumi)fb for a Higgs boson of mass 125.4GeV decaying to two isolated photons that have transverse momentum greater than 35% and 25% of the diphoton invariant mass and each with absolute pseudorapidity less than 2.37. Four additional fiducial cross sections and two cross-section limits are presented in phase space regions that test the theoretical modelling of different Higgs boson production mechanisms, or are sensitive to physics beyond the Standard Model. Differential cross sections are also presented, as a function of variables related to the diphoton kinematics and the jet activity produced in the Higgs boson events. The observed spectra are statistically limited but broadly in line with the theoretical expectations

Search for squarks and gluinos in events with isolated leptons, jets and missing transverse momentum at s√=8 TeV with the ATLAS detector

The results of a search for supersymmetry in final states containing at least one isolated lepton (electron or muon), jets and large missing transverse momentum with the ATLAS detector at the Large Hadron Collider are reported. The search is based on proton-proton collision data at a centre-of-mass energy s√=8 TeV collected in 2012, corresponding to an integrated luminosity of 20 fb−1. No significant excess above the Standard Model expectation is observed. Limits are set on supersymmetric particle masses for various supersymmetric models. Depending on the model, the search excludes gluino masses up to 1.32 TeV and squark masses up to 840 GeV. Limits are also set on the parameters of a minimal universal extra dimension model, excluding a compactification radius of 1/R c = 950 GeV for a cut-off scale times radius (ΛR c) of approximately 30

Measurement of the production of a W boson in association with a charm quark in pp collisions at √s = 7 TeV with the ATLAS detector

The production of a W boson in association with a single charm quark is studied using 4.6 fb−1 of pp collision data at s√ = 7 TeV collected with the ATLAS detector at the Large Hadron Collider. In events in which a W boson decays to an electron or muon, the charm quark is tagged either by its semileptonic decay to a muon or by the presence of a charmed meson. The integrated and differential cross sections as a function of the pseudorapidity of the lepton from the W-boson decay are measured. Results are compared to the predictions of next-to-leading-order QCD calculations obtained from various parton distribution function parameterisations. The ratio of the strange-to-down sea-quark distributions is determined to be 0.96+0.26−0.30 at Q 2 = 1.9 GeV2, which supports the hypothesis of an SU(3)-symmetric composition of the light-quark sea. Additionally, the cross-section ratio σ(W + +c¯¯)/σ(W − + c) is compared to the predictions obtained using parton distribution function parameterisations with different assumptions about the s−s¯¯¯ quark asymmetry

Evidence for the Higgs-boson Yukawa coupling to tau leptons with the ATLAS detector

Results of a search for H → τ τ decays are presented, based on the full set of proton-proton collision data recorded by the ATLAS experiment at the LHC during 2011 and 2012. The data correspond to integrated luminosities of 4.5 fb−1 and 20.3 fb−1 at centre-of-mass energies of √s = 7 TeV and √s = 8 TeV respectively. All combinations of leptonic (τ → `νν¯ with ` = e, µ) and hadronic (τ → hadrons ν) tau decays are considered. An excess of events over the expected background from other Standard Model processes is found with an observed (expected) significance of 4.5 (3.4) standard deviations. This excess provides evidence for the direct coupling of the recently discovered Higgs boson to fermions. The measured signal strength, normalised to the Standard Model expectation, of µ = 1.43 +0.43 −0.37 is consistent with the predicted Yukawa coupling strength in the Standard Model

Measurement of the cross-section of high transverse momentum vector bosons reconstructed as single jets and studies of jet substructure in pp collisions at √s = 7 TeV with the ATLAS detector

This paper presents a measurement of the cross-section for high transverse momentum W and Z bosons produced in pp collisions and decaying to all-hadronic final states. The data used in the analysis were recorded by the ATLAS detector at the CERN Large Hadron Collider at a centre-of-mass energy of √s = 7 TeV;{\rm Te}{\rm V}$and correspond to an integrated luminosity of$4.6\;{\rm f}{{{\rm b}}^{-1}}$. The measurement is performed by reconstructing the boosted W or Z bosons in single jets. The reconstructed jet mass is used to identify the W and Z bosons, and a jet substructure method based on energy cluster information in the jet centre-of-mass frame is used to suppress the large multi-jet background. The cross-section for events with a hadronically decaying W or Z boson, with transverse momentum${{p}_{{\rm T}}}\gt 320\;{\rm Ge}{\rm V}$and pseudorapidity$|\eta |\lt 1.9$, is measured to be${{\sigma }_{W+Z}}=8.5\pm 1.7$ pb and is compared to next-to-leading-order calculations. The selected events are further used to study jet grooming techniques

Search for squarks and gluinos with the ATLAS detector in final states with jets and missing transverse momentum using √s=8 TeV proton-proton collision data

A search for squarks and gluinos in final states containing high-p T jets, missing transverse momentum and no electrons or muons is presented. The data were recorded in 2012 by the ATLAS experiment in s√=8 TeV proton-proton collisions at the Large Hadron Collider, with a total integrated luminosity of 20.3 fb−1. Results are interpreted in a variety of simplified and specific supersymmetry-breaking models assuming that R-parity is conserved and that the lightest neutralino is the lightest supersymmetric particle. An exclusion limit at the 95% confidence level on the mass of the gluino is set at 1330 GeV for a simplified model incorporating only a gluino and the lightest neutralino. For a simplified model involving the strong production of first- and second-generation squarks, squark masses below 850 GeV (440 GeV) are excluded for a massless lightest neutralino, assuming mass degenerate (single light-flavour) squarks. In mSUGRA/CMSSM models with tan β = 30, A 0 = −2m 0 and μ > 0, squarks and gluinos of equal mass are excluded for masses below 1700 GeV. Additional limits are set for non-universal Higgs mass models with gaugino mediation and for simplified models involving the pair production of gluinos, each decaying to a top squark and a top quark, with the top squark decaying to a charm quark and a neutralino. These limits extend the region of supersymmetric parameter space excluded by previous searches with the ATLAS detector